NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Thursday that its second quarter revenues rose 48 percent year over year, thanks to continued momentum from its kidney transplant test AlloSure.

For the three months ended June 30, the diagnostics company said revenues rose to $17.8 million from $12.0 million in Q2 2017, beating analysts' average estimate of $15.5 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.